HLA-Cw6/KIR2DS1 Drug Candidates
NewLab is finalizing the characterization of interaction between the HLA Cw6 gene product and its receptor, KIR2DS1. A prototype peptide drug designed to inhibit this binding interaction has been developed. Experimentation is underway to optimize candidate drug design for optimal biological effect. Potential clinical indications for these drugs are varied and common.
Next Generation Peptide T
NewLab owns intellectual property around Peptide T, a drug that was originally developed by the National Institute of Health in the United States for the treatment of HIV. A chance finding in the clinical experience with Peptide T in the treatment of HIV was rapid resolution of psoriasis plaques. This observation led to other promising studies including development of second generation Peptide T. NewLab has designed a series of modified Peptide T molecules aimed at addressing the original drug’s short half-life limitation. The chemical modification strategies were developed based on extensive experience in peptide drug chemistry in the pharmaceutical industry coupled with the latest technical expertise in peptide drug modification aimed at half-life extension. NewLab is testing these proprietary drug candidates in experimental systems used for the commercial development of psoriasis drugs, paving the way for commercialization of the next generation Peptide T products.
|
|
|
|
|